Dow climbs 691 points as healthcare firms make progress towards coronavirus treatment

Healthcare stocks led gains, rallying on developments in rapid testing and a potential vaccine for COVID-19.
President Donald Trump on Sunday extended federal social-distancing guidelines to April 30, abandoning earlier hopes the US economy could reopen by Easter.
Confirmed global cases of COVID-19 have surged past 735,000, and the death toll continues to rise.
Read more on Business Insider .

US stocks rose Monday as investors weighed expanded efforts in the US to combat the novel coronavirus, as well as increased hopes for rapid testing and a possible vaccine. Healthcare stocks were notable outperformers.

Abbott Laboratories jumped as much as 13% after it received emergency-use approval from the US Food and Drug Administration. The company developed a COVID-19 test that delivers positive results in five minutes and negative ones in 13 minutes.

Johnson & Johnson also gained as much as 8% after it said that it has selected a lead candidate for a coronavirus vaccine and plans to start testing in September.

Here's where the major US indexes stood at the market close on Monday:

S&P 500 : 2,626.65 up 3.4%
Dow Jones Industrial Average : 22,327.48, up 3.2% (691 points)
Nasdaq composite : 7,774.15, up 3.6%

Investors were also encouraged by signs the US government is taking coronavirus-containment efforts seriously. President Donald Trump said on Sunday that federal social-distancing measures in the US would continue through April 30 , casting aside earlier statements he made about easing coronavirus restrictions and reopening the US economy by April 12.

Global cases of COVID-19 surged to more than 735,500 and deaths rose to nearly 35,000 .

Oil slumped Monday, closing at an 18-year low, as the coronavirus pandemic continues to weigh on demand, which has halted travel and slowing economic activity around the world. Meanwhile, a price war between Russia and Saudi Arabia has threatened to create a record supply glut.

"We should expect volatility, and the market to retest lows for awhile," Ed Campbell, portfolio manager and managing director at QMA told Business Insider. "We are going to be in the midst of this process for awhile."

Investors are looking ahead for signs that lockdowns are working in countries outside of Asia, according to Campbell. A peak in new cases and eventual decline could be an important inflection point for markets because it would create the sense that the lockdown was successful in containing the virus in other Western economies, he said.

"At that point we'd be on the road to returning to some semblance of normalcy," Campbell said.

In addition, Congress may be working on extra stimulus relief, Reuters reported . The bill would be the fourth legislative-aid package meant to bolster the US economy amid the coronavirus pandemic. Trump signed a historic $2 trillion bill into law last week.

"Investors are likely assuming that in a matter of several weeks or a couple of months, we may return to normal, but that may prove to be a very risky bet," Hussein Sayed, the chief market strategist at FXTM, told Business Insider. Until investors see a "major decline" in the number of COVID-19 cases, "any rally in risk assets may prove to be temporary," he said.

Investors will be up against more economic data this week that will show the impact of the coronavirus outbreak on the US. The first quarter ends on Tuesday, the last day of March, marking a key day for businesses that may struggle to pay bills. On Wednesday, US manufacturing PMI will be released, followed by weekly jobless claims Thursday and the March jobs report Friday.

NOW WATCH: A big-money investor in juggernauts like Facebook and Netflix breaks down the '3rd wave' firms that are leading the next round of tech disruption